

1 **CD4 T cells are rapidly depleted from tuberculosis granulomas following acute SIV co-**  
2 **infection**

3

4 Authors: Taylor W. Foreman<sup>1</sup>, Christine E. Nelson<sup>1</sup>, Keith D. Kauffman<sup>1</sup>, Nickiana E. Lora<sup>1</sup>, Caian  
5 L. Vinhaes<sup>2,3</sup>, Danielle E. Dorosky<sup>1</sup>, Shunsuke Sakai<sup>1</sup>, Felipe Gomez<sup>4</sup>, Joel D. Fleegle<sup>4</sup>, Melanie  
6 Parham<sup>5</sup>, Shehan R. Perera<sup>6</sup>, Cecilia S. Lindestam Arlehamn<sup>7</sup>, Alessandro Sette<sup>7</sup>, Tuberculosis  
7 Imaging Program<sup>4</sup>, Jason M. Brenchley<sup>8</sup>, Artur T.L. Queiroz<sup>2,9</sup>, Bruno B. Andrade<sup>2,3</sup>, Juraj Kabat<sup>10</sup>,  
8 Laura E. Via<sup>4,11,12</sup>, Daniel L. Barber<sup>1#</sup>

9

10 <sup>1</sup>T lymphocyte Biology Section, Laboratory of Parasitic Diseases, National Institutes of Allergy  
11 and Infectious Disease, National Institutes of Health, Bethesda, MD, USA;

12 <sup>2</sup>Multinational Organization Network Sponsoring Translational and Epidemiological Research  
13 (MONSTER) Initiative, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil;

14 <sup>3</sup>Bahiana School of Medicine and Public Health (EBMSP), Salvador, Brazil;

15 <sup>4</sup>Division of Intramural Research, National Institutes of Allergy and Infectious Disease, National  
16 Institutes of Health, Bethesda, MD, USA;

17 <sup>5</sup>Axle Informatics, National Center for Advancing Translational Sciences, Bethesda, MD, USA;

18 <sup>6</sup>Department of Electrical and Computer Engineering, The Ohio State University, Columbus, OH,  
19 USA;

20 <sup>7</sup>Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA;

21 <sup>8</sup>Barrier Immunity Section, Laboratory of Viral Diseases, National Institutes of Allergy and  
22 Infectious Disease, National Institutes of Health, Bethesda, MD, USA;

23 <sup>9</sup>Data and Knowledge Integration Center for Health (CIDACS), Instituto Gonçalo Moniz, Salvador,  
24 Bahia, Brazil;

25 <sup>10</sup>Biological Imaging Section, Research Technologies Branch, National Institutes of Allergy and  
26 Infectious Disease, National Institutes of Health, Bethesda, MD, USA;

27 <sup>11</sup>Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National  
28 Institutes of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA;

29 <sup>12</sup>Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department  
30 of Pathology, University of Cape Town, Observatory, South Africa.

31

32 ‡Note: The members of the NIAID/DIR Tuberculosis Imaging Program can be found at the end of  
33 the Acknowledgments

34

35 #Corresponding author: Dr. Daniel Barber, [barberd@niaid.nih.gov](mailto:barberd@niaid.nih.gov)

36

37 Author Contributions: T.W.F. conceived and led the study. T.W.F. and D.L.B. designed the  
38 research. T.W.F., C.E.N., K.D.K., N.E.L., D.E.D, and S.S. performed the experiments. T.W.F.,  
39 C.E.N., A.T.L.Q., C.L., B.B.A., and D.L.B. analyzed the Luminex results. T.W.F., C.E.N., and  
40 D.L.B. analyzed the flow cytometry results. T.W.F., J.K., and D.L.B. analyzed the 4D imaging  
41 results. M.P. and S.R.P. wrote scripts necessary for 4D imaging analysis. C.S.L.A., A.S., and  
42 J.M.B. provided critical reagents. Tuberculosis Imaging Program (TBIP) managed logistics,  
43 performed NHP manipulations including infection, necropsy, PET/CT scanning, and imaging  
44 analysis. F.G. and J.D.F. analyzed the PET/CT data. L.E.V. supervised TBIP and designed the  
45 analysis for PET/CT data. T.W.F. and D.L.B. wrote the manuscript with all authors contributing  
46 with feedback.

47

48 Acknowledgements: We are very grateful to the veterinary care provided by Dr. Rashida Moore  
49 and the NIAID, Comparative Medicine Branch Animal Biosafety Level 3 facility staff. We also

50 thank Drs. Alan Sher and Eduardo P. Amaral for discussion of data and feedback on the  
51 manuscript. We would like to thank the members of the NIAID/DIR Tuberculosis Imaging  
52 Program for their assistance: Ayan Abdi, Joel D. Fleegle, Felipe Gomez, Michaela K. Piazza,  
53 Katelyn M. Repoli, Becky Y. Sloan, Ashley L. Butler, April M. Walker, Danielle M. Weiner, Michael  
54 J. Woodcock, and Alexandra Vathauer.

55

56 Funding: This work was supported in part by the Intramural AIDS Research Fellowship, Office of  
57 Intramural Training and Education, NIH (T.W.F.), the Division of Intramural Research, National  
58 Institutes of Allergy and Infectious Diseases, NIH (D.L.B., J.M.B., & L.E.V.), the Brazilian National  
59 Council for Scientific and Technological Development (C.L.V., A.T.L.Q., & B.B.A.), the Intramural  
60 Research Program of Fundação Oswaldo Cruz (A.T.L.Q. & B.B.A.).

61

62 The contents of this publication do not necessarily reflect the views or policies of the Department  
63 of Health and Human Services, nor does mention of trade names, commercial products, or  
64 organizations imply endorsement by the United States government. The authors declare no  
65 conflict of interest.

66

67 **ABSTRACT**

68 The HIV-mediated decline in circulating CD4 T cells correlates with increased risk of active  
69 tuberculosis (TB)<sup>1-4</sup>. However, HIV/*Mycobacterium tuberculosis* (Mtb) co-infected individuals also  
70 have an increased incidence of TB prior to loss of CD4 T cells in blood<sup>3,5</sup>, raising the possibility  
71 that HIV co-infection leads to disruption of CD4 T cell responses at the site of lung infection  
72 before they are observed systemically. Here we used a rhesus macaque model of SIV/Mtb co-  
73 infection to study the early effects of acute SIV infection on CD4 T cells in pulmonary Mtb  
74 granulomas. Two weeks after SIV co-infection CD4 T cells were dramatically depleted from  
75 granulomas, before significant bacterial outgrowth, disease reactivation as measured by PET-  
76 CT imaging, or CD4 T cell loss in blood, airways, and lymph nodes. Mtb-specific CD4 T cells,  
77 CCR5-expressing, in granulomas were preferentially depleted by SIV infection. Moreover, CD4  
78 T cells were preferentially depleted from the granuloma core and lymphocyte cuff relative to B  
79 cell-rich regions, and live imaging of granuloma explants showed that SIV co-infection reduced  
80 T cell motility. Thus, Mtb-specific CD4 T cells in pulmonary granulomas may be decimated before  
81 many patients even experience the first symptoms of acute HIV infection.



82 **MAIN**

83 Human immunodeficiency virus (HIV) infection gradually depletes circulating CD4 T cells  
84 leading to the development of acquired immunodeficiency syndrome (AIDS) and impaired host  
85 resistance to microbial infections. CD4 T cells are essential for control of *Mycobacterium*  
86 *tuberculosis* (Mtb) infection, and tuberculosis (TB) is the leading cause of death in persons living  
87 with HIV (PLWH)<sup>6</sup>. The extent of peripheral CD4 T cell depletion in PLWH correlates with  
88 increasing risk of developing active TB<sup>3,4</sup>. However, PLWH with normal-to-high CD4 T cell counts  
89 in the blood also have increased incidence of active TB<sup>3</sup>. The mechanistic basis for the elevated  
90 risk of TB in individuals with normal CD4 T cell counts is incompletely understood, but may  
91 reflect detrimental impact of antiviral inflammation (e.g. type I interferons) on anti-mycobacterial  
92 innate immunity<sup>7-9</sup>, impairment of macrophage function<sup>10,11</sup>, or preferential depletion of CD4 T  
93 cells in tissues compared to circulation<sup>12-14</sup>.

94 Mtb persists in granulomas, complex structures comprised of multiple immune cell types  
95 that reproducibly position themselves relative to one another<sup>15</sup>. Although variable by many  
96 respects, granulomas can be generally described by a few key features including: an oft-  
97 necrotic, macrophage-rich, core where mycobacteria are primarily located<sup>16</sup>, a lymphocyte-rich  
98 cuff circumscribing the macrophage core<sup>17</sup>, and B cell-rich tertiary lymphoid-like substructures  
99 referred to as Granuloma-Associated Lymphoid Tissue (GrALT) located within the lymphocyte  
100 cuff or found as proximal granuloma satellites<sup>18,19</sup>. CD4 T cells are primarily found in the  
101 lymphocyte cuff but can also be seen interacting with macrophages in the core or with B cells in  
102 GrALT<sup>17</sup>. Due to the difficulty of studying human lung infections, little is understood about the  
103 effects of HIV infection on Mtb granulomas. Previous studies have shown that SIV infection of  
104 macaques recapitulates the gradual loss of circulating CD4 T cells and eventual development of  
105 active tuberculosis disease as seen in humans<sup>20-23</sup>. Here we examine the very early effects of SIV  
106 infection on CD4 T cell responses at the site of Mtb infection in rhesus macaques to ask if CD4

107 T cells within the granuloma microenvironment are differentially susceptible to dysfunction and  
108 depletion during SIV infection as compared to T cells in circulation or lymphoid tissues.

## 109 RESULTS

110 To study the early effects of SIV co-infection in Mtb-infection, 10 Indian rhesus macaques  
111 were intrabronchially infected with ~56 CFU of *Mtb* H37Rv bilaterally (Fig. 1a). Animals were  
112 monitored for signs of disease for 10-11 weeks before allocation into groups that either remained  
113 *Mtb mono*-infected (n=5) or were intravenously infected with 3,000 TCID<sub>50</sub> of SIVmac239 (n=5).  
114 The study was concluded exactly fourteen days after SIV infection. Animals did not show signs  
115 of tuberculosis disease as measured by weight loss or fever over the course of the study (Fig.  
116 S1a-b). Plasma SIV viral loads increased in most animals until day 14 (Fig. 1b). Using RNAscope  
117 to study SIV localization, viral RNA was detected in granulomas, surrounding lung tissue, and  
118 lymph nodes (Fig. 1c-d). (Fig. 1d, S2). Spot density of RNAScope for SIV RNA was higher in  
119 granulomas than lymph node and surrounding lung tissues (Fig. 1e). Spots of viral RNA staining  
120 in granulomas were further analyzed for their distribution in the core, cuff, or GrALT (confirmed  
121 as CD20-rich areas). Viral RNA staining was most dense in GrALT regions as compared to the  
122 core and cuff of the granuloma (Fig. 1f). Although it is difficult to distinguish between viral  
123 particles and infected cells with this technique, we did find that the size of individual spots was  
124 significantly different between tissues. Lymph nodes contained a higher frequency of large spots  
125 >100  $\mu\text{m}^2$  (possibly representing infected cells) compared to the granulomas (Fig. 1g). Overall,  
126 these results demonstrate that granulomas become heavily infected with virus quickly after SIV  
127 infection.

128 To determine if SIV co-infection led to changes in TB lesions, macaques were imaged  
129 using <sup>18</sup>F-FDG PET-CT scanning prior to and 12 days after SIV co-infection (Fig. 1h). There were  
130 no changes in the number of lesions that could be identified by PET-CT imaging after SIV  
131 infection, however at necropsy, more granulomas were isolated from co-infected macaques (Fig.  
132 S1c). We found no impact of SIV infection on granuloma volumes as measured by volume of  
133 abnormal voxels or density range (Fig. 1i) or glycolytic activity as measured by <sup>18</sup>F-FDG uptake

134 (Fig. 1j). Although statistically significant, the difference in the size of granulomas was not  
135 notable, and while there was a trend for increased cellularity of the SIV granulomas in co-infected  
136 animals, the difference did not reach statistical significance (Fig. S1d-e). Mycobacterial loads in  
137 individual granulomas were statistically significantly increased in the co-infected animals, but the  
138 difference was less than 2 fold (~625 CFU in SIV-uninfected granulomas vs. ~955 CFU in co-  
139 infected granulomas) (Fig. 1k). Lastly, there was no significant correlation between SIV viral and  
140 mycobacterial loads in granulomas, indicating that the granulomas with lower viral loads were  
141 not different due to their mycobacterial burdens (Fig. 1k). Thus, as expected we did not observe  
142 tuberculosis disease reactivation in the first two weeks after SIV infection, however it is possible  
143 that bacterial loads were just beginning to increase and new granulomas to form.

144         Next, we examined the effect of acute SIV infection on the pattern of soluble markers of  
145 inflammation in granulomas. The markers that correlated with bacterial loads were different in  
146 mono- vs co-infected granulomas (Fig. 2a). Concentrations of CCL2, CCL4, IL-8, and IL-1RA  
147 were positively correlated with mycobacterial burden in the granulomas of both groups of  
148 animals. In contrast, IL-6 and IL-1 $\beta$  levels only correlated with CFU in mono-infected granulomas,  
149 and CCL3, TNF, CXCL12 and GM-CSF correlated with CFU only in the SIV co-infected  
150 granulomas (Fig 2a). SIV loads in granulomas were most strongly correlated with CXCL11 (an  
151 IFN-inducible CXCR3 ligand) and to a lesser extent with CCL3 and CCL4 (both CCR5 ligands)  
152 as well as TNF, IL-18, and IL-23 (Fig 2a). SIV-infected granulomas contained higher levels of  
153 CCL3 and IL-8, but the differences were less than ~2 fold, and the granulomas from SIV infected  
154 and co-infected animals contained very similar levels of the soluble mediators measured here  
155 (Fig. 2b). Thus, although SIV infection did not dramatically impact the overall levels of soluble  
156 mediators in the first 2 weeks after infection, it altered the relationship between mycobacterial  
157 loads and inflammatory mediators in granulomas.

158 To further characterize the impact of early SIV infection on the inflammatory milieu of  
159 granulomas, we next used network density analysis of Spearman correlations<sup>24,25</sup> to quantify the  
160 interconnectivity of these variables (Fig. 2c). After SIV infection multiple soluble mediators, in  
161 particular several chemokines, had increased numbers of correlations with each other, and the  
162 overall network density was significantly higher in co-infected granulomas (Fig. 2d). Most  
163 notably, CXCL12 had no significant correlations with other mediators in the mono-infected  
164 granulomas but was the largest node in the co-infected granulomas. Comparing the degrees of  
165 connection from the bootstrap analysis highlighted the increased connectivity of CCL3, CCL4,  
166 and CXCL12 in co-infected granulomas while IL-1 $\beta$  showed increased connectivity in mono-  
167 infected granulomas (Fig. 2e). Such increased network density has previously been shown to  
168 reflect heightened inflammatory states<sup>25-27</sup>. Interestingly, IFN $\alpha$  was not detected in the  
169 granulomas from either group of animals, so we are unable to implicate virus-induced type IFN  
170 response in these changes in the granuloma inflammatory milieu after SIV infection (Fig 2f). When  
171 taken together with the overall lack of major increases in the total concentrations of most  
172 mediators, and the very small increase in bacterial loads, we speculate these data indicate that  
173 at 14 days after viral infection, SIV may be just beginning to drive increased mycobacterial loads  
174 and perturb inflammatory responses.

175 We next examined T cell composition after co-infection. The frequency of CD4 T cells  
176 was not significantly different across peripheral blood mononuclear cells (PBMCs), pulmonary  
177 lymph nodes (LN), splenocytes, and bronchoalveolar lavage (BAL). In contrast, CD4 T cells were  
178 greatly reduced in SIV co-infected granulomas on day 14 after SIV infection (Fig. 3a, gating  
179 strategy Fig S3). Accordingly, there was no difference in the frequency of CD8 T cells in the BAL,  
180 LN or spleen, but an increase was observed in granulomas from co-infected animals (Fig. S3d).  
181 The difference in the CD4:CD8 T cell ratio was different between *Mtb mono*-infected and *Mtb/SIV*  
182 *co*-infected granulomas ( $p < 0.0001$ ), and the decline in the CD4:CD8 cell ratio was correlated

183 with SIV viral burden (Fig. 3b). Absolute numbers of CD4 T cells were significantly reduced in co-  
184 infected compared to mono-infected granulomas, while CD8 T cell numbers were retained (Fig.  
185 3c). 60.5% of co-infected granulomas contained less than 20 CD4 T cells and were therefore  
186 excluded from further phenotypic analysis. MTB300 peptide-specific CD4 T cells were  
187 maintained in the pulmonary LN and BAL after SIV co-infection but were strikingly reduced in  
188 granulomas, where the majority of granulomas no longer contained any Mtb-specific CD4 T cells  
189 (Fig. 3d-e, S3e). The Mtb peptide pool used in this study is not optimized for restimulation of  
190 CD8 T cells, however, Ag-specific CD8 T cells could still be detected and were not different in  
191 any tissue sites of the mono and co-infected animals (Fig. S3f-g). Taken together these results  
192 demonstrate that CD4 T cells, and particularly Mtb-specific CD4 T cells, are depleted from the  
193 granulomas prior to detectable depletion in the peripheral tissues or even BAL, and the decline  
194 in CD4 T cells is correlated with the viral burden of individual granulomas.

195 CD4 T cells are variably susceptible to SIV-mediated depletion based on activation and  
196 differentiation state and expression viral entry co-receptors (e.g. CCR5)<sup>14,28</sup>. To examine the  
197 differential susceptibility of granuloma CD4 T cell subsets to SIV co-infection, we analyzed T  
198 cells for the expression of chemokine receptors CCR5, CCR6, CXCR3, CXCR5, and the  
199 transcription factor eomesodermin (eomes) (Fig. S4a). We focused on the bulk population of non-  
200 naïve (CD95<sup>+</sup>) CD4 T cells, due to the near complete absence of Mtb-specific CD4 T cells in most  
201 of the co-infected granulomas. There was a significant reduction in CCR5, CCR6, and CXCR3-  
202 expressing cells, no difference in eomes<sup>+</sup> cells, and a slight increase in CXCR5<sup>+</sup> CD4 T cells in  
203 co-infected compared to mono-infected granulomas (Fig. 4a-b). In contrast, among CD8 T cells  
204 there was an increase in CCR5<sup>+</sup> and eomes<sup>+</sup> cell in co-infected granulomas (Fig. 4c). Consistent  
205 with the granulomas, similar differences were also seen for both activated CD4 and CD8 T cells  
206 in the pulmonary LN (Fig. S4b-c). Boolean gating of these markers allowed us to discriminate  
207 between several relevant T cell subsets: CXCR3<sup>+</sup>CCR6<sup>-</sup> Th1 cells, CCR6<sup>+</sup>CXCR3<sup>+</sup> T<sub>H</sub>1\* cells,

208 CCR6<sup>+</sup>CXCR3<sup>-</sup> Th17-like and CXCR5<sup>+</sup> Tfh-like cells (Fig. S4a). We were able to further subdivide  
209 each of these subsets based on expression of the viral entry co-receptor CCR5, as well as  
210 eomes. This accounted for >90% of all memory T cells in the granulomas (Fig. S4d-e). Among  
211 both Th1\* and Th1 cells, we found that the CCR5<sup>+</sup>eomes<sup>-</sup> subset of these effector lineages was  
212 preferentially depleted (Fig. 4d). In contrast, both CCR5<sup>+</sup>eomes<sup>+</sup> Th1 and Th1\* cells did not  
213 display evidence of preferential depletion. In CD8 T cells, there was a significant increase in the  
214 frequency of CCR5<sup>+</sup>CXCR3<sup>+</sup>eomes<sup>+</sup> T cells and commensurate reduction in  
215 CCR5<sup>+</sup>CXCR3<sup>+</sup>eomes<sup>-</sup> and CCR5<sup>-</sup>CXCR3<sup>+</sup>eomes<sup>-</sup> T cells from co-infected granulomas (Fig. 4e).  
216 Interestingly, the increase in CCR5<sup>+</sup> CD8 T cells is consistent with the elevated levels of CCL3  
217 we observed in granulomas. Thus, while the overall population of CD4 T cells in granulomas is  
218 greatly reduced, there is evidence of preferential depletion of the subsets of Th1 and Th1\* CD4  
219 T cells that express CCR5 but lack eomes. Future experiments are needed to explore the role of  
220 eomes in determining the susceptibility of CCR5<sup>+</sup> CD4 T cells to SIV-mediated depletion.

221 To determine the early effects of SIV infection on granuloma architecture and intralesional  
222 T cell trafficking, we performed live-imaging of granuloma thick-section explants<sup>24</sup>. Live sections  
223 of granulomas were stained with antibodies to CD4, CD20, and CD11b and imaged at 37°C for  
224 1-2 hours (Fig 5a, Supplemental movie). Quality control was performed to remove tracks with  
225 less than 5 spots or whose movement was restricted by edges in the X, Y, and Z planes (Fig.  
226 S5). The X- and Y-start position of the tracks analyzed from the granuloma shown in (Fig. 5a)  
227 can be seen for CD4<sup>+</sup> tracks and CD20<sup>+</sup> tracks (Fig. 5b). As expected, the number of tracks  
228 normalized to the volume of tissue imaged in each granuloma was significantly lower for CD4<sup>+</sup>  
229 tracks in co-infected compared to mono-infected granulomas, but there was no difference in  
230 CD20<sup>+</sup> tracks between the groups (Fig. 5c). Accordingly, the ratio between CD4<sup>+</sup> and CD20<sup>+</sup>  
231 tracks was statistically significantly reduced in granulomas imaged from co-infected macaques  
232 (Fig. S6a). We next quantified the localization of tracks within the macrophage-rich core,

233 lymphocyte-rich cuff, or B cell-rich GrALT regions of granulomas (Fig. 5b). In SIV co-infected  
234 granulomas, the frequency of CD4<sup>+</sup> tracks localized to GrALT was increased due to a reduction  
235 in the absolute number of tracks found in the core and cuff (Fig. 5d-e). In contrast, the distribution  
236 of CD20<sup>+</sup> tracks to different regions of the granuloma was not different between mono- and co-  
237 infected granulomas (Fig. S6b-c). These results demonstrate CD4 T cells in the core and cuff  
238 (i.e., CD4 T cells best positioned to interact with Mtb-infected macrophages), are preferentially  
239 depleted early after SIV infection.

240         We next compared CD4 T cell and B cell movement in mono- and co-infected  
241 granulomas. Individual tracks were categorized based on their mean speed and the variation in  
242 speed into 3 major patterns of cellular motility: stopped cells, stuttering cells, or steadily moving  
243 cells (Fig. 5f). CD4<sup>+</sup> tracks displayed reduced motility evidenced by a significant increase in  
244 stopped tracks and concordant decrease in steadily moving tracks (Fig. 5g). This difference was  
245 not seen in CD20<sup>+</sup> tracks where there was no difference stopped, steady, or stuttering tracks in  
246 mono- vs co-infected granulomas (Fig. 5g). This difference was even more significant when  
247 pairing the analysis of CD4<sup>+</sup> and CD20<sup>+</sup> tracks from the same granuloma indicating the changes  
248 in motility are not granuloma specific but CD4 T cell specific (Fig. S6d). Taken together these  
249 results demonstrate that SIV co-infection significantly decreased CD4 T cell movement in  
250 granulomas.



## 251 **DISCUSSION**

252 CD4 T cell depletion is considered the primary mechanism by which HIV infection leads  
253 to the inability to control growth of Mtb, but little is understood about the impact of HIV infection  
254 on CD4 T cells at the sites of mycobacterial infection in the tissues. Here we used a non-human  
255 primate model of TB and SIV co-infection to study the early events of SIV infection on CD4 T  
256 cells in Mtb granulomas. We find that CD4 T cells in granulomas are highly sensitive to SIV-  
257 mediated depletion compared to other tissues. It is not clear why granuloma CD4 T cells are so  
258 susceptible to SIV-mediated depletion. However, it is reminiscent of the massive loss of CD4 T  
259 cells in the gastrointestinal tract of PLWH and of non-human primate species that develop AIDS  
260 after SIV infection<sup>28-31</sup>. Moreover, lung parenchymal CD4 T cells are more susceptible than BAL  
261 CD4 T cells to HIV mediated depletion in a humanized mouse model of HIV infection<sup>32</sup>. The  
262 selective loss of granuloma CD4 T cells may be due to enhanced permissiveness of these T cells  
263 to SIV infection as compared to CD4 T cells in other locations (e.g. CCR5-expressing T cells are  
264 enriched in granulomas)<sup>33</sup>. It is also possible that the microenvironment the granuloma itself may  
265 facilitate depletion of CD4 T cells. For example, activated macrophages efficiently take up  
266 infected CD4 T cells<sup>34</sup>, and granulomas are densely packed with macrophages. Importantly,  
267 these two possibilities are not mutually exclusive.

268 In some granulomas, there was a near total loss of CD4 T cells within 14 days, indicating  
269 that most or maybe all T cells in granulomas are susceptible to depletion during SIV co-infection.  
270 Nonetheless, our data also indicate that some CD4 T cells in granulomas are even more  
271 susceptible than others. Previous reports have shown that in persons latently infected with Mtb  
272 HIV co-infection preferentially infects and depletes Mtb-specific CD4 T cells<sup>14,35-38</sup>. Perhaps most  
273 importantly, our data show that Mtb-specific CD4 T cells were greatly reduced in frequency in  
274 SIV co-infected granulomas long before depletion manifested in blood. CCR5-expressing Th1  
275 and Th1\* cells were also reduced in frequency in SIV co-infected granulomas. This is expected

276 as CCR5 is a co-receptor for viral entry. Interestingly, we found that CCR5<sup>+</sup> cells that also  
277 expressed the transcription factor eomes were not reduced in frequency in co-infected lesions.  
278 The mechanisms underlying this apparent differential sensitivity of CCR5<sup>+</sup>eomes<sup>+</sup> CD4 T cells is  
279 not clear. Expression of CCR5 ligands in CD4 T cells has been shown previously to be associated  
280 decreased viral replication in viremic patients and elite controllers<sup>39,40</sup>, and eomes<sup>+</sup> CD4 T cells  
281 have been shown to produce high levels of CCL3/MIP-1 $\alpha$ <sup>41</sup>, which may partly explain the  
282 increase of soluble CCL3 in granulomas. Therefore, the preservation of CCR5<sup>+</sup>eomes<sup>+</sup> CD4 T  
283 cells in granulomas may reflect protection by CCR5-ligand production.

284 We observed a regionalized depletion where CD4 T cells were lost to a lesser degree in  
285 GrALT as compared to the core and cuff of the granuloma. This was not due to a lack of viral  
286 replication, as the highest amounts of virus in the granuloma as detected by RNAscope was in  
287 GrALT structures. Germinal centers have been proposed to be an ‘immunologically privileged’  
288 site for viral persistence, perhaps due to the inability of cytotoxic T cells to interact with infected  
289 T<sub>FH</sub> CD4 T cells, so it is possible that less effective killing by SIV-specific cytotoxic T cells may  
290 be responsible for the decreased depletion of GrALT-resident CD4 T cells<sup>42,43</sup>.

291 We also found that the CD4 T cells remaining in SIV co-infected granulomas  
292 demonstrated reduced motility, raising the possibility that SIV-mediated suppression of CD4 T  
293 cell movement is another mechanism of immunosuppression. HIV infection has been shown to  
294 result in reduced motility of CD4 T cells in response to chemokines in vitro<sup>44,45</sup>. We should  
295 additionally point out, however, that CD4 T cells in granulomas may also stop moving as a result  
296 of interaction with peptide-presenting cells<sup>46</sup>, so the importance of this observation to the loss  
297 of bacterial control is not clear. Nonetheless, CD4 T cell interaction with infected macrophages  
298 is necessary for control of intracellular mycobacterial growth<sup>47,48</sup>, and it is possible that reduced  
299 trafficking of the few remaining CD4 T cells in the granulomas further impairs microbial immunity.  
300 We do not know if this defect in T cell motility occurs in other tissues, as we have only imaged

301 lung granulomas for this work. Future studies are needed to address the broader possibility that  
302 lentiviral infection results in immunosuppression not only by killing T cells but also by limiting the  
303 mobility the ones that remain.

304 Collectively, these data show how SIV infection is even more detrimental for Mtb-specific  
305 immunity than previous appreciated. We should point out that we do not exclude other  
306 mechanisms of viral infection-enhanced susceptibility to Mtb infection. Indeed, cytomegalovirus  
307 infection in humans has been associated with enhanced risk of TB<sup>49,50</sup> and influenza infection in  
308 mice has been shown to enhance Mtb infection<sup>51</sup>. SIV preferentially kills Mtb-specific CD4 T cells  
309 in granulomas, CD4 T cells phenotypically most correlated with immune control, and CD4 T cells  
310 in the subregions of granulomas that are best positioned to interact with Mtb-infected  
311 macrophages. To make things worse, it impairs the trafficking of the CD4 T cells that remain.  
312 Most patients are just beginning to notice signs and symptoms of HIV infection 14 days after  
313 primary infection, yet here we demonstrate that CD4 T cells within the granuloma have already  
314 been depleted. These data provide a potential explanation of the increased risk of TB reactivation  
315 prior to the loss of peripheral CD4 T cells in HIV infection. Understanding the granuloma-specific  
316 mechanisms CD4 T cell susceptibility to SIV-mediated depletion may lead to intervention  
317 strategies to preserve anti-tuberculosis immunity in co-infected individuals.

## 318 **METHODS**

### 319 Study Design and Infections

320 Rhesus macaques originally from the Morgan Island NIH breeding colony were housed  
321 in biocontainment according to the Animal Welfare Act and the Guide for the Care and Use of  
322 Laboratory Animals within a AAALAC international-accredited animal biosafety level-3 vivarium.  
323 Daily enrichment was provided for the macaques. All procedures were performed using  
324 anesthetics according to the approved NIAID DIR Animal Care and Use Committee study  
325 proposal LPD-25E. Additionally, animals were scanned at regular intervals with a LFER 150  
326 PT/CT scanner (Mediso, Inc., Hungary) using  $^{18}\text{F}$ FDG (0.5 mCi/kg) and tubercular lung disease, as  
327 well as, individual lesion characteristics were analyzed on serial scans as described  
328 previously<sup>24,52</sup>. The object of this study was to understand the effects of acute SIV on *Mtb*-  
329 specific immune responses. To achieve this, 10 macaques were intrabronchially infected with  
330 ~56 CFU of *Mycobacterium tuberculosis* (*Mtb*) strain H37Rv-mCardinal (kindly provided by Dr.  
331 Clifton Barry III, chief of the Tuberculosis Research Section, Laboratory of Clinical Immunology  
332 and Microbiology, NIAID) bilaterally using 2-mL of saline each into the right and left lower lobes  
333 ( $14.0 \pm 3.77$  CFU/mL). After *Mtb* infection, animals were monitored for clinical signs of  
334 tuberculosis such as weight loss and pyrexia for 10-11 weeks. Thereafter animals were randomly  
335 assigned to one of two groups where the *mono*-infection group remained SIV-naïve and the co-  
336 infection group was intravenously injected with 3,000 TCID<sub>50</sub> of SIVmac239. For tissue collection  
337 exactly 14 days post SIV infection, a co-infection animal along with a time-matched *Mtb* mono-  
338 infected animal was euthanized according to American Veterinary Medical Association  
339 guidelines.

340

341 Tissue Processing for Cells, Bacteria, and Virus

342 Blood was collected using EDTA-tubes and cells isolated using Ficoll-Paque Density  
343 Centrifugation (GE Life Sciences, Canada). Bronchoalveolar lavage (BAL) was collected using a  
344 modified feeding tube inserted through the trachea into the lower pulmonary lobes and lavaged  
345 using ~60mL of sterile saline. Fluid was then filtered using a 100-micron filter and centrifuged for  
346 the collection of cells. Tissues were taken for analysis at the time of necropsy. For single cell  
347 suspensions, spleen and lymphnodes were homogenized using gentleMACSs dissociators  
348 (Miltenyi Biotec, Germany) and filtered through a 100-micron filter while isolated granulomas  
349 were mashed through a 100-micron filter using a syringe plunger. Homogenates from  
350 granulomas and tissues were serially diluted and plated on 7H11 agar plates incubated at 37°C  
351 for 3-4 weeks before quantification. Granuloma homogenate was taken for RNA isolation using  
352 RNeasy Plus Kits and stored at -80°C (Qiagen, USA). Quantification of viral burden was done  
353 using TaqPath 1-step RT-qPCR Master Mix (Thermo Fisher Scientific, USA) and primers/probes  
354 sets targeting SIVmac239 (Eurofins Scientific, USA) or GAPDH (Thermo Fisher Scientific, USA).  
355 Reactions were completed in triplicates for 40 cycles using FAM dyes. Plasma was filter-  
356 sterilized and analyzed for plasma viral load by RT-qPCR by Quantitative Molecular Diagnostics  
357 Core at the Frederick National Laboratory.

358

#### 359 Cell stimulation and Flow cytometry

360 Cells were stimulated with 2 µg/mL of MTB300 epitope peptide pool (A&A Labs, USA) in  
361 the presence of brefeldin A and monensin (Thermo Fisher Scientific, USA) for 6 hours at 37°C in  
362 Complete media (RPMI-1640 with 10% fetal calf serum (FCS), 1% Sodium pyruvate, 1%  
363 penicillin and streptomycin, 25 mM Hepes, and 2 mM l-glutamate). Fresh cells were incubated  
364 in blocking buffer containing 1% FCS, 1µg/mL Human FC block (BD Biosciences, USA) for 1-6  
365 hours at 4°C. Cells were then stained using fixable live/dead stain for 20 minutes at room  
366 temperature. Surface antibody staining was done in PBS containing 1% FCS and 1X Brilliant

367 Stain Buffer (BD Biosciences, USA) for 20 minutes at room temperature. After fixation and  
368 permeabilization using Foxp3/Transcription Factor Staining Kit (eBiosciences, USA), intracellular  
369 antibody staining was done in PBS containing 1% FCS, 1X Brilliant Stain Buffer, and 1X  
370 Permeabilization reagent for 30 minutes at 4°C. Samples were acquired using a FACSymphony  
371 cytometer (BD Biosciences, USA) and data analyzed using FlowJo 10 (BD Biosciences, USA).  
372 Gating strategies are shown in figures S3-4.

373

374 Multiplex cytokine analysis

375 Granuloma homogenates were filter-sterilized and processed for soluble protein marker  
376 concentrations using the Invitrogen Cytokine and Chemokine 30-Plex ProcartaPlex Kit (Thermo  
377 Fisher Scientific, USA) according to manufacturer protocol. Samples were acquired using a  
378 MAGPIX with xPONENT software (Luminex Corporation, USA). Soluble marker protein levels  
379 were normalized to total protein levels measured by Quant-iT protein Assay Kit (Thermo Fisher  
380 Scientific, USA).

381

382 4D Confocal Imaging of Granulomas

383 Isolated granulomas were kept on ice until embedding in PBS with 2% agarose. The  
384 tissue was cut into 300-micron thick sections using a Leica VT1000 S Vibrating Blade Microtome  
385 (Leica Microsystems, USA) housed in Class II, Biosafety hood within a BSL3 laboratory. Sections  
386 of tissue were incubated in 1X PBS supplemented with 10% FCS, isotype-specific blocking  
387 antibodies, and Human FC Block (BD Biosciences, USA) for 2-8 hours at 4°C. After blocking,  
388 tissues were stained with antibodies CD4, CD20, and CD11b for 2-12 hours at 4°C with  
389 intermittent shaking. Tissues were then washed and placed into chamber slides containing  
390 Complete Imaging Media (Complete media made with phenol red-free RPMI) supplemented with  
391 ProLong Live Antifade Reagent (Thermo Fisher Scientific, USA). After incubation in a 5% CO<sub>2</sub>

392 incubation chamber at 37°C for 1 hour, the chambered slide was imaged using Leica SP5  
393 inverted confocal microscope with environmental chamber to maintain the sample humidified at  
394 37°C (Leica Microsystems, USA). Sections were serially imaged over the course of 1-2 hours  
395 and compiled using LAS X software (Leica Microsystems, USA). Image analysis was performed  
396 using Imaris software (Bitplane, Switzerland) for quantification of individual cells using the spot  
397 function to track their movement over time. Data from tracks were exported, processed through  
398 a custom Python 3 script to select the parameters to include in the exported files, and then  
399 imported into FlowJo 10 software (BD Biosciences, USA) for data visualization and analysis as  
400 described in Fig S6. Briefly, tracks that were limited in movement by the edges of the X-, Y-, or  
401 Z-plane were excluded from analysis. Using the X- and Y-starting point of a track, cells could be  
402 localized to different areas in the granuloma. Finally, track movement was categorized into three  
403 different forms. Stopped and Steady tracks both had  $\leq 0.90$   $\mu\text{m}/\text{minute}$  track speed variation but  
404 were characterized by  $\leq 2.0$   $\mu\text{m}/\text{minute}$  or  $> 2.0$   $\mu\text{m}/\text{minute}$  mean track speed, respectively.  
405 Stuttering tracks had any mean track speed but were characterized by track speed variation  
406  $> 0.90$   $\mu\text{m}/\text{minute}$ .

407

#### 408 RNAscope and Image Analysis

409 Formalin Fixed Paraffin embedded tissues sections were cut into 10-micron thick  
410 sections using RNase precautions and used for RNAscope *in situ* hybridization staining for viral  
411 RNA (ACD Biotechne, USA). Slides were dewaxed using xylene and ethanol and then underwent  
412 epitope retrieval using heat induced low-pH methods according to the manufacturer. Slides were  
413 then treated with diluted protease plus for 20 min at 40°C and endogenous peroxidases blocked  
414 using hydrogen peroxide for 10 min at room temperature. Probes for SIVmac239, containing 83  
415 separate pairs of probes spanning the proviral gag, vif, pol, tat, env, vpx, vpr, nef, and rev genes,  
416 were used for single color immunohistochemistry with hematoxylin counter-staining using the

417 RNAscope 2.5 HD Assay-RED (ACD Biotechne, USA). Immunocytochemically stained slides  
418 were imaged using Aperio VERSA (Leica Microsystems, USA) and analyzed using a custom  
419 quPath script to identify spots with pixel size 0.5-microns, background radius 8-microns, median  
420 radius 8-microns, sigma 0.75-microns, minimum area 2.0-microns, maximum area 400-microns,  
421 with threshold of 0.25. Spots were then colocalized to granuloma regions using annotation tabs  
422 for each area of the granuloma which were identified according to the different hematoxylin  
423 counter-staining pattern and CD20 staining.

424

#### 425 Statistical analyses

426 All statistical analyses were conducted using GraphPad Prism V8 (GraphPad Software,  
427 USA) except for when specified otherwise. Data were tested for Gaussian distribution using the  
428 D'Agostino's K-square test. For group comparisons, individual tests vary and are denoted in each  
429 figure legend but include two-tailed unpaired T-tests, Mann-Whitney *U* (when parameter  
430 compared were not normally distributed), One-way ANOVA with correction for multiple tests  
431 using Tukey Multiple Comparison test corrections, non-linear regression analysis of semi-log  
432 line, or simple linear regression analysis. Multiplex Luminex assay data were analyzed using R  
433 4.0.2 packages *igraph*, *ggplot2*, *viridis*, *ComplexHeatmap*, *Hmisc*, with *p.adjust* function. Fold  
434 change was measured and significance test by Student's T test with False Discovery Ratio  
435 correction. Correlation analyses were performed using the Spearman's rank test with 100  
436 bootstrap replicates. Bootstrap threshold value was defined in 80 replicates. Significant values  
437 were corrected using False Discovery Ratio. Any place p-value are reported in asterisks \* p<0.05,  
438 \*\* p<0.01, \*\*\* p<0.001, and \*\*\*\* p<0.0001, ns=non-significant.



439 **Figure legends**

440 **Figure 1. Lung Mtb granulomas are heavily infected by SIV rapidly after co-infection.** (A) 10

441 Rhesus macaques were intrabronchially infected with Mycobacterium tuberculosis H37Rv for

442 10-11 weeks and 5 macaques were subsequently infected with SIVmac239 intravenously. Both

443 groups were followed for another 14 days. (B) Acute viral infection was tracked by measuring

444 plasma viral loads after co-infection. (C) Example image of RNAscope staining for SIV viral RNA

445 in a co-infected granuloma. (vRNA shown in red and nuclei counterstained light blue) (D)

446 Quantification of individual spots was performed and compared to different microanatomical

447 locations in the granuloma as indicated and verified by immunohistochemical staining for B cell

448 clusters. (E) Quantification of the number of SIV spots analyzed in uninvolved lung tissue and

449 lymph nodes compared to granulomas. (F) Different regions of the granuloma were further

450 characterized demonstrating increased viral burden in GrALT. (G) Distribution violin plots of the

451 size in  $\mu\text{m}^2$  of individual spots with the frequency of  $>100 \mu\text{m}$  spots indicated above the boxed

452 area. (H)  $^{18}\text{F}$ FDG PET-CT scans were performed immediately before SIV infection and at day 12

453 post co-infection which allowed tracking individual lesions. (I) The change in volume of each

454 lesion as measured in voxels ( $0.5 \text{ mm}^3$ ) with with abnormal hounsfield unit density (-400 to 200

455 HU) on CT was insignificant from pre- to post-SIV infection. (J)  $^{18}\text{F}$ FDG uptake, expressed as the

456 total lesion glycolytic (TLG) activity in standardized uptake value/body weight (SUVbw)/mL, of

457 each lesion was compared pre- to post-SIV infection and also found to be insignificant. (K)

458 Individual granulomas were isolated at the time of necropsy for determination of bacterial load.

459 (L) RNA isolated from each granuloma was assayed for viral quantification and compared to

460 bacterial burden. Statistical analysis was calculated using (E-F) one-way ANOVA, (I-J) student's

461 unpaired T-tests, (K) Mann-Whitney U-test, or (L) nonlinear regression analysis. ns = non-

462 significant, \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$  \*\*\*\*  $p < 0.0001$

463

464 **Figure 2. Early changes in soluble mediators in Mtb granulomas after SIV co-infection. (A)**

465 Granuloma homogenates were assayed for soluble mediators of inflammation, values normalized  
466 to protein levels and by Z-score and compared to bacterial and viral burdens. Heatmap  
467 visualization of 23 markers within mono-infected (left) and co-infected (right) granulomas with  
468 indicated bacterial burden for each granuloma shown below the heatmap, and spearman  
469 correlations with pathogen burdens to the right. Correlations were calculated intra-group and  
470 only values with false discovery rate below 0.01 highlighted as significant. (B) The log<sub>2</sub> fold  
471 change of soluble markers between mono- and co-infected groups were calculated and  
472 compared for significance. (C) Correlation network analysis using Spearman's rank test were  
473 performed and visualized using circus plots where the size of the circle indicates the number of  
474 significant correlations. (D) The overall distribution of network density degree and (E) individual  
475 degrees of connectivity of CCL3, CCL4, CXCL12, and IL-1 $\beta$  in 100 bootstrap replicates. (F) The  
476 levels of IFN $\alpha$  in granuloma homogenates of all samples shown in correlation to viral burden.  
477 Statistical analysis was performed using (A) Spearman's rank test for correlations, (B, D-E)  
478 student's T test with false discovery ratio correction, or (E) Wilcoxon signed-rank test.

479

480 **Figure 3. Mtb-specific CD4 T cells are massively depleted in granulomas two weeks after**

481 **SIV co-infection.** (A) Flow cytometric analysis of PBMC's, pulmonary lymph nodes (LN),  
482 splenocytes, bronchoalveolar lavage (BAL), and individual granulomas showing the percentage  
483 of CD3<sup>+</sup> T cells that are CD4<sup>+</sup>. (B) Comparison of the CD4:CD8 ratio in individual granulomas to  
484 the viral burden. (C) Quantification of the number of total CD4<sup>+</sup> and CD8<sup>+</sup> T cells in granulomas.  
485 LOD = Limit of detection. (D) Example flow cytometry plots of Mtb antigen stimulation of CD4<sup>+</sup> T  
486 cells in pulmonary LN, BAL, and granulomas from mono- and co-infected (top and bottom row,  
487 respectively). (E) Frequency and absolute number of antigen specific CD4<sup>+</sup> T cells in granulomas  
488 after restimulation with a Mtb peptide pool. Statistical analysis was calculated using (A) students

489 unpaired T-tests, (B) nonlinear regression analysis, or (C, E) Mann-Whitney U-test. \*\*  $p < 0.01$ , \*\*\*\*  
490  $p < 0.0001$

491

492 **Figure 4. CCR5-expressing Th1 and Th1\* cells in granulomas are preferentially depleted**

493 **by SIV co-infection.** (A) Example flow cytometry plots of activated CD4 T cells in granulomas

494 expressing chemokine receptors CCR5, CCR6, CXCR3, CXCR5, and the transcription factor

495 eomesodermin (eomes). (B-C) Expression of markers in non-naïve CD4 T cells and CD8 T cells.

496 (D-E) Boolean analysis of the same markers where the ten populations of cells shown comprise

497 >90% of total population of CD4 and CD8 T cells. Statistical analysis was calculated using

498 Student's unpaired T-tests. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$

499

500 **Figure 5. SIV co-infection alters the spatial distribution and intralesional trafficking of CD4**

501 **T cells in Mtb granulomas.** (A-B) Example still image of a granuloma used for 4D imaging (CD4

502 is cyan, CD20 is green, and CD11b is purple) where distilled cellular tracks from CD4<sup>+</sup> and CD20<sup>+</sup>

503 cells shown in the X- and Y-start position. (C) Absolute number of tracks normalized to the

504 volume of tissue imaged. (D-E) Localization of CD4<sup>+</sup> tracks within the macrophage rich core, the

505 lymphocyte dense cuff, or the granuloma-associated lymphoid tissue that forms within the cuff

506 as the frequency of or absolute number of total CD4<sup>+</sup> tracks in the granuloma. (F) Example plots

507 of the movement of CD4<sup>+</sup> tracks from a single granuloma with frequency denoted in the top right

508 corner. (G) Quantification of the movement of CD4<sup>+</sup> tracks and CD20<sup>+</sup> tracks as denoted as

509 stopped, steadily moving, or stuttering. Statistical analysis was calculated using students

510 unpaired T-tests. \*  $p < 0.05$ , \*\*  $p < 0.01$

511

512 **Supplemental Figure 1. Clinical parameters in mono- and co-infected macaques.** (A-B)

513 Weight change as percent deviation from starting weight and rectal temperature over the course

514 of the study. (C) Quantification of the number of visible lesions by PET/CT imaging at pre- and  
515 post-SIV viral infection along with the number of lesions isolated at the time of necropsy. (D) The  
516 diameter of individual granulomas measured at necropsy. (E) Number of cells isolated per  
517 granuloma after processing for single cell suspensions. Statistical analysis was calculated using  
518 (C) paired Student's T test or (D-E) Mann-Whitney U-test. ns = not significant

519

520 **Supplemental Figure 2. RNAscope imaging quantification of SIV RNA.** (A-B) RNAscope  
521 image of a SIV-infected granuloma with SIV viral RNA shown in red with a light blue nuclei  
522 counterstain with higher-magnification image inset. (C-D) Quantification of viral spots using  
523 QuPath Image analysis, shown as yellow spots with the same high-magnification image shown  
524 above. (E) Example gating pattern for the localization of spots throughout the granuloma. (F)  
525 Image of SIV-naïve granuloma to demonstrate the high specificity of in situ hybridization.

526

527 **Supplemental Figure 3. T cell gating strategy.** Shown is an example flow cytometric gating  
528 strategy for a single cell suspension from a pulmonary LN. (A) Parent gates for lymphocytes, live  
529 cells, and singlets with progression to CD3<sup>+</sup> T cells and frequency of CD4<sup>+</sup> to CD8<sup>+</sup> T cells.  
530 Detailed analysis of T cells starting from parent gates and progressing to (B) CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>-</sup>  
531 CD95<sup>+</sup> T cells or (C) CD3<sup>+</sup>CD4<sup>-</sup>CD8<sup>+</sup>CD95<sup>+</sup> T cells. (D) Frequency of CD3<sup>+</sup> T cells that are CD8<sup>+</sup>  
532 in the blood, pulmonary LN, spleen, and BAL. (E) Frequency of Mtb-specific CD4<sup>+</sup> T cells in the  
533 pulmonary LN and BAL at the time of necropsy. (F) Example flow cytometry plots of CD8<sup>+</sup> T cells  
534 stimulated with Mtb peptide pools (14-mer epitopes) and the (G) quantification of antigen-  
535 specific CD8<sup>+</sup> T cells in granulomas, BAL, and pulmonary LN's. Statistical analysis was  
536 calculated using Student's unpaired T-tests. \*\*\*\* p<0.0001

537

538 **Supplemental Figure 4. Differential depletion of phenotypically distinct CD4 T cell subsets.**

539 (A) Example gating strategy used for the Boolean analysis of CCR5, CCR6, CXCR3, CXCR5, and  
540 eomes in both CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Parent gate represents gating strategy shown in  
541 Supplemental Figure 3 as labelled above initiating plots. (B-C) Expression of these markers on  
542 activated CD4 and CD8 T cells from the pulmonary LN. (D-E) Quantification of the percent of  
543 total CD4 and CD8 T cells comprised of the 10 populations shown in Fig. 4D-E. Statistical  
544 analysis was calculated using students unpaired T-tests. \* p<0.05, \*\*\*\* p<0.0001

545

546 **Supplemental Figure 5. Analysis strategy for 4D imaging of granulomas.** (A) Example plots

547 of the stringent parameters used to isolate CD4 and CD20 tracks. Only tracks with more than or  
548 equal to 5 individual spots were used, with cells excluded that were inhibited by the Z, X, or Y  
549 boundaries. (B) The tracks analyzed for this granuloma with comparison of a still-image. (C) High-  
550 magnification image shows spots analyzed overlaid with the actual image. (D) Example flow  
551 plots of cellular movement in two different granulomas showing the range of movement and  
552 indicated movement characteristics.

553

554 **Supplemental Figure 6. Analysis of cellular movement in granulomas.** (A) Ratio of CD4 to

555 CD20 tracks in all granulomas analyzed by 4D imaging. (B-C) Quantification of the frequency  
556 and absolute number of CD20 tracks from the core, cuff, and GrALT. (D) Paired analysis of  
557 CD4 and CD20 tracks from the same granuloma to show the reduction in movement as  
558 specific to T cells and not the whole granuloma. Statistical analysis was calculated using (A-C)  
559 students unpaired T-tests and (D) paired T-tests. \* p<0.05, \*\*\* p<0.001, \*\*\*\* p<0.0001

560  
561

## REFERENCES

### 562 Uncategorized References


- 563 1. Geldmacher, C., Zumla, A. & Hoelscher, M. Interaction between HIV and *Mycobacterium*  
564 *tuberculosis*: HIV-1-induced CD4 T-cell depletion and the development of active  
565 tuberculosis. *Curr Opin HIV AIDS* **7**, 268-275 (2012).
- 566 2. Okoye, A.A. & Picker, L.J. CD4(+) T-cell depletion in HIV infection: mechanisms of  
567 immunological failure. *Immunol Rev* **254**, 54-64 (2013).
- 568 3. Glynn, J.R., *et al.* Effects of duration of HIV infection and secondary tuberculosis  
569 transmission on tuberculosis incidence in the South African gold mines. *AIDS* **22**, 1859-  
570 1867 (2008).
- 571 4. van der Sande, M.A., *et al.* Incidence of tuberculosis and survival after its diagnosis in  
572 patients infected with HIV-1 and HIV-2. *AIDS* **18**, 1933-1941 (2004).
- 573 5. Esmail, H., *et al.* The Immune Response to *Mycobacterium tuberculosis* in HIV-1-  
574 Coinfected Persons. *Annu Rev Immunol* **36**, 603-638 (2018).
- 575 6. *Global Tuberculosis Report 2019*, (Geneva: World Health Organization, 2019).
- 576 7. Mayer-Barber, K.D., *et al.* Host-directed therapy of tuberculosis based on interleukin-1  
577 and type I interferon crosstalk. *Nature* **511**, 99-103 (2014).
- 578 8. Zhang, L., Jiang, X., Pfau, D., Ling, Y. & Nathan, C.F. Type I interferon signaling mediates  
579 *Mycobacterium tuberculosis*-induced macrophage death. *J Exp Med* **218**(2021).
- 580 9. Sandler, N.G., *et al.* Type I interferon responses in rhesus macaques prevent SIV infection  
581 and slow disease progression. *Nature* **511**, 601-605 (2014).
- 582 10. DiNapoli, S.R., Hirsch, V.M. & Brenchley, J.M. Macrophages in Progressive Human  
583 Immunodeficiency Virus/Simian Immunodeficiency Virus Infections. *J Virol* **90**, 7596-7606  
584 (2016).
- 585 11. Kuroda, M.J., *et al.* High Turnover of Tissue Macrophages Contributes to Tuberculosis  
586 Reactivation in Simian Immunodeficiency Virus-Infected Rhesus Macaques. *J Infect Dis*  
587 **217**, 1865-1874 (2018).
- 588 12. Brenchley, J.M., *et al.* CD4+ T cell depletion during all stages of HIV disease occurs  
589 predominantly in the gastrointestinal tract. *J Exp Med* **200**, 749-759 (2004).
- 590 13. Picker, L.J., *et al.* Insufficient production and tissue delivery of CD4+ memory T cells in  
591 rapidly progressive simian immunodeficiency virus infection. *J Exp Med* **200**, 1299-1314  
592 (2004).
- 593 14. Geldmacher, C., *et al.* Preferential infection and depletion of *Mycobacterium tuberculosis*-  
594 specific CD4 T cells after HIV-1 infection. *J Exp Med* **207**, 2869-2881 (2010).
- 595 15. Pagan, A.J. & Ramakrishnan, L. The Formation and Function of Granulomas. *Annu Rev*  
596 *Immunol* **36**, 639-665 (2018).
- 597 16. Mattila, J.T., *et al.* Microenvironments in tuberculous granulomas are delineated by  
598 distinct populations of macrophage subsets and expression of nitric oxide synthase and  
599 arginase isoforms. *J Immunol* **191**, 773-784 (2013).
- 600 17. Kauffman, K.D., *et al.* Defective positioning in granulomas but not lung-homing limits CD4  
601 T-cell interactions with *Mycobacterium tuberculosis*-infected macrophages in rhesus  
602 macaques. *Mucosal Immunol* **11**, 462-473 (2018).

- 603 18. Ulrichs, T., *et al.* Human tuberculous granulomas induce peripheral lymphoid follicle-like  
604 structures to orchestrate local host defence in the lung. *J Pathol* **204**, 217-228 (2004).
- 605 19. Phuah, J.Y., Mattila, J.T., Lin, P.L. & Flynn, J.L. Activated B cells in the granulomas of  
606 nonhuman primates infected with *Mycobacterium tuberculosis*. *Am J Pathol* **181**, 508-514  
607 (2012).
- 608 20. Foreman, T.W., *et al.* CD4+ T-cell-independent mechanisms suppress reactivation of  
609 latent tuberculosis in a macaque model of HIV coinfection. *Proc Natl Acad Sci U S A* **113**,  
610 E5636-5644 (2016).
- 611 21. Diedrich, C.R., *et al.* SIV and *Mycobacterium tuberculosis* synergy within the granuloma  
612 accelerates the reactivation pattern of latent tuberculosis. *PLoS Pathog* **16**, e1008413  
613 (2020).
- 614 22. Larson, E.C., *et al.* Pre-existing Simian Immunodeficiency Virus Infection Increases  
615 Expression of T Cell Markers Associated with Activation during Early *Mycobacterium*  
616 *tuberculosis* Coinfection and Impairs TNF Responses in Granulomas. *J Immunol* (2021).
- 617 23. Ganatra, S.R., *et al.* Antiretroviral therapy does not reduce tuberculosis reactivation in a  
618 tuberculosis-HIV coinfection model. *J Clin Invest* **130**, 5171-5179 (2020).
- 619 24. Kauffman, K.D., *et al.* PD-1 blockade exacerbates *Mycobacterium tuberculosis* infection in  
620 rhesus macaques. *Sci Immunol* **6**(2021).
- 621 25. Vinhaes, C.L., *et al.* Dissecting disease tolerance in *Plasmodium vivax* malaria using the  
622 systemic degree of inflammatory perturbation. *PLoS Negl Trop Dis* **15**, e0009886 (2021).
- 623 26. Tiburcio, R., *et al.* Dynamics of T-Lymphocyte Activation Related to Paradoxical  
624 Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in Persons With  
625 Advanced HIV. *Front Immunol* **12**, 757843 (2021).
- 626 27. Bruyn, E.D., *et al.* Inflammatory profile of patients with tuberculosis with or without HIV-  
627 1 co-infection: a prospective cohort study and immunological network analysis. *Lancet*  
628 *Microbe* **2**, e375-e385 (2021).
- 629 28. Okoye, A., *et al.* Progressive CD4+ central memory T cell decline results in CD4+ effector  
630 memory insufficiency and overt disease in chronic SIV infection. *J Exp Med* **204**, 2171-  
631 2185 (2007).
- 632 29. Veazey, R.S., *et al.* Identifying the target cell in primary simian immunodeficiency virus  
633 (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV  
634 infection in vivo. *J Virol* **74**, 57-64 (2000).
- 635 30. Mattapallil, J.J., *et al.* Massive infection and loss of memory CD4+ T cells in multiple tissues  
636 during acute SIV infection. *Nature* **434**, 1093-1097 (2005).
- 637 31. Brenchley, J.M., *et al.* Differential Th17 CD4 T-cell depletion in pathogenic and  
638 nonpathogenic lentiviral infections. *Blood* **112**, 2826-2835 (2008).
- 639 32. Corleis, B., *et al.* HIV-1 and SIV Infection Are Associated with Early Loss of Lung Interstitial  
640 CD4+ T Cells and Dissemination of Pulmonary Tuberculosis. *Cell Rep* **26**, 1409-1418 e1405  
641 (2019).
- 642 33. Paiardini, M., *et al.* Low levels of SIV infection in sooty mangabey central memory CD4(4)(+) T  
643 cells are associated with limited CCR5 expression. *Nat Med* **17**, 830-836 (2011).
- 644 34. Calantone, N., *et al.* Tissue myeloid cells in SIV-infected primates acquire viral DNA  
645 through phagocytosis of infected T cells. *Immunity* **41**, 493-502 (2014).





- 646 35. Bunjun, R., *et al.* Th22 Cells Are a Major Contributor to the Mycobacterial CD4(+) T Cell  
647 Response and Are Depleted During HIV Infection. *J Immunol* **207**, 1239-1249 (2021).
- 648 36. Strickland, N., *et al.* Characterization of *Mycobacterium tuberculosis*-Specific Cells Using  
649 MHC Class II Tetramers Reveals Phenotypic Differences Related to HIV Infection and  
650 Tuberculosis Disease. *J Immunol* (2017).
- 651 37. Geldmacher, C., *et al.* Early depletion of *Mycobacterium tuberculosis*-specific T helper 1  
652 cell responses after HIV-1 infection. *J Infect Dis* **198**, 1590-1598 (2008).
- 653 38. Amelio, P., *et al.* HIV Infection Functionally Impairs *Mycobacterium tuberculosis*-Specific  
654 CD4 and CD8 T-Cell Responses. *J Virol* **93**(2019).
- 655 39. Kinter, A.L., *et al.* HIV replication in CD4+ T cells of HIV-infected individuals is regulated by  
656 a balance between the viral suppressive effects of endogenous beta-chemokines and the  
657 viral inductive effects of other endogenous cytokines. *Proc Natl Acad Sci U S A* **93**, 14076-  
658 14081 (1996).
- 659 40. Casazza, J.P., *et al.* Autocrine production of beta-chemokines protects CMV-Specific CD4  
660 T cells from HIV infection. *PLoS Pathog* **5**, e1000646 (2009).
- 661 41. Buggert, M., *et al.* Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T  
662 cells during health and HIV disease. *PLoS Pathog* **14**, e1006973 (2018).
- 663 42. Mylvaganam, G.H., *et al.* Dynamics of SIV-specific CXCR5+ CD8 T cells during chronic SIV  
664 infection. *Proc Natl Acad Sci U S A* **114**, 1976-1981 (2017).
- 665 43. Cadena, A.M., *et al.* Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-  
666 infected Rhesus Macaques. *Nat Commun* **12**, 1474 (2021).
- 667 44. Cecchinato, V., *et al.* Impairment of CCR6+ and CXCR3+ Th Cell Migration in HIV-1  
668 Infection Is Rescued by Modulating Actin Polymerization. *J Immunol* **198**, 184-195 (2017).
- 669 45. Perez-Patrigeon, S., *et al.* HIV infection impairs CCR7-dependent T-cell chemotaxis  
670 independent of CCR7 expression. *AIDS* **23**, 1197-1207 (2009).
- 671 46. Egen, J.G., *et al.* Intravital imaging reveals limited antigen presentation and T cell effector  
672 function in mycobacterial granulomas. *Immunity* **34**, 807-819 (2011).
- 673 47. Grace, P.S. & Ernst, J.D. Suboptimal Antigen Presentation Contributes to Virulence of  
674 *Mycobacterium tuberculosis* In Vivo. *J Immunol* **196**, 357-364 (2016).
- 675 48. Yang, J.D., *et al.* *Mycobacterium tuberculosis*-specific CD4+ and CD8+ T cells differ in their  
676 capacity to recognize infected macrophages. *PLoS Pathog* **14**, e1007060 (2018).
- 677 49. Muller, J., *et al.* Cytomegalovirus infection is a risk factor for tuberculosis disease in  
678 infants. *JCI Insight* **4**(2019).
- 679 50. Martinez, L., *et al.* Cytomegalovirus acquisition in infancy and the risk of tuberculosis  
680 disease in childhood: a longitudinal birth cohort study in Cape Town, South Africa. *Lancet*  
681 *Glob Health* **9**, e1740-e1749 (2021).
- 682 51. Redford, P.S., *et al.* Influenza A virus impairs control of *Mycobacterium tuberculosis*  
683 coinfection through a type I interferon receptor-dependent pathway. *J Infect Dis* **209**, 270-  
684 274 (2014).
- 685 52. Beites, T., *et al.* Plasticity of the *Mycobacterium tuberculosis* respiratory chain and its  
686 impact on tuberculosis drug development. *Nat Commun* **10**, 4970 (2019).
- 687













**Figure 1**





**Figure 3**





**Figure 5**